Recce Pharma (ASX:RCE) will dose patients with 4g of its R327 intravenous solution to treat UTIs in Phase I/II trials following safety board approval.
The move reflects the latest positive step forward for Recce’s UTI clinical program, focusing on in-house anti-infective R327.
R327 is the company’s foremost drug of interest applicable as either an IV solution or a topical gel in the treatment of internal infections and also those which affect wounds post surgery.
So far, the company is trying to ascertain what the baseline ample dose for an IV infusion of R327 truly is, with the company greenlit in recent iterations to up dosages, and, shorten down infusion times.
Recce’s ultimate goal is to create a one-use-required drug that takes as little time and effort to administer as possible in the successful one-dose eradication of UTIs, a problem more commonly affecting women than men.
Six participants will make up the cohort of patients being administered 4,000mg, a first for Recce, with dosing to commence in “near weeks.”
This trial ultimately puts Recce on the track towards reaching a final verdict on the efficacy of R327 for UTIs.
“We’re thrilled the independent safety committee has unanimously clearly an increased R327 dose to 4,000mg, over a 30 minute fast I.V. infusion,” Recce chief James Graham said.
“The high concentration potential to administer a broad spectrum anti- infective underscores the potential of a novel treatment for millions of patients worldwide that suffer from Urinary Tract Infection/Urosepsis each year.”
RCE last traded at 69c.